Dosage considerations with perindopril for systemic hypertension.

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Background:

• Hypertension is a prevalent condition affecting blood pressure (BP) regulation.
• Angiotensin-converting enzyme (ACE) inhibitors are a key class of antihypertensive medications.
• Perindopril erbumine is a prodrug converted to its active form, perindoprilat, which inhibits ACE.

Purpose of the Study:

• To evaluate the efficacy and tolerability of perindopril erbumine in managing hypertension.
• To assess the pharmacokinetic profile and duration of action of perindopril.
• To investigate the effects of perindopril on vascular properties beyond BP reduction.

Main Methods:

• Clinical studies assessing systolic and diastolic blood pressure reduction.
• Pharmacokinetic analysis to determine perindoprilat distribution and elimination.
• Evaluation of trough-to-peak ratios for sustained antihypertensive effect.
• Assessment of incidence of first-dose hypotension and effects of missed doses.
• Studies on arterial distensibility, compliance, and vascular remodeling.

Main Results:

• Perindopril erbumine effectively lowers systolic and diastolic BP in mild-to-moderate hypertension.
• Achieves 24-hour efficacy with a trough-peak ratio of 75-100%.
• Lower incidence of first-dose hypotension compared to other ACE inhibitors.
• Antihypertensive effect persists for 24-48 hours after a missed dose.
• Improves arterial distensibility and compliance, with potential for vascular remodeling independent of BP lowering.
• Well-tolerated in the elderly; combination with diuretics enhances BP reduction.

Conclusions:

• Perindopril erbumine provides effective and sustained 24-hour blood pressure control.
• Offers advantages in specific patient populations, including those prone to hypotension.
• Demonstrates beneficial effects on vascular structure and function.
• Renal clearance necessitates dosage adjustment in patients with impaired renal function.